Sign in

    Daniel T. Scavilla

    President and Chief Executive Officer at Globus Medical Inc
    Board
    Since April 2022
    Age
    59 years
    Education
    Holds a B.S. in Finance and Organizational Behavior from LaSalle University and an MBA in International Management from Temple University.
    Tenure
    Joined GMED in May 2015 as CFO, later served as Executive Vice President and President of Trauma, and has been serving as President and Chief Executive Officer since April 2022.

    Also at Globus Medical Inc

    DCP
    David C. Paul
    Chairman of the Board and Executive Chairman
    KWP
    Keith W. Pfeil
    Chief Operating Officer and Chief Financial Officer
    KGH
    Kelly G. Huller
    Senior Vice President, General Counsel, and Corporate Secretary

    About

    Daniel T. Scavilla has had a long and varied career in the medical device industry, demonstrating a consistent ability to drive growth and innovation through strategic leadership initiatives.

    Prior to his GMED tenure, he spent 28 years at a major healthcare corporation in various senior financial and operational roles, honing skills in financial management and business operations that have profoundly influenced his leadership style.

    Outside of his primary role at GMED, his participation on boards and governance committees reflects a commitment to advancing healthcare technologies and ethical business practices, further cementing his reputation as a transformative leader in the industry.

    $GMED Performance Under Daniel T. Scavilla

    Past Roles

    OrganizationRoleDate RangeDetails
    Impulse Dynamics Board of Directors November 2021 – July 2023 Served on the board of a privately held medical technology company specializing in minimally invasive treatment for heart failure patients
    Globus Medical Chief Financial Officer May 2015 – April 2022 Joined GMED as CFO prior to promotion to CEO
    Globus Medical Executive Vice President, Chief Commercial Officer, and President of Trauma N/A – April 2022 Launched the Orthopedics and Trauma business unit at GMED
    Johnson & Johnson Chief Financial Officer, Global Vice President Finance & Business Operations of J&J Vision N/A Oversaw a business with $4 billion in annual global revenue
    Johnson & Johnson Chief Financial Officer, Worldwide Vice President Finance of Advanced Sterilization Products N/A Led the infection prevention business within the MedTech unit
    Johnson & Johnson - McNeil Consumer Healthcare (now Kenvue) Financial Management N/A Held financial management roles
    Johnson & Johnson - Centocor Biologics Financial Management N/A Held financial management roles
    Janssen Pharmaceutical (Cilag Schaffhausen Operations) Financial Management N/A Held financial management roles in Switzerland

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$463,500 Annually in 2023 Fixed base salary
    Bonus$150,000 One-time in 2023 Awarded in recognition of the successful NuVasive acquisition closing
    All Other Compensation$32,980 Annually in 2023 Comprises group health insurance benefits ($16,812 for group health insurance ), Company 401(k) plan matching, vehicle allowance, YMCA membership reimbursement, and insurance premiums

    Performance Compensation

    Data from  FY 2023

    Annual Non-Equity Incentive Plan

    Metric [USD Millions/Percent]**Details
    Revenue Goal$1,125
    Threshold (0% Payout)75% or less of the revenue goal
    Target (100% Payout)97.5% of revenue goal resulting in a target payout of $900,000
    Maximum (145% Payout)110% of revenue goal
    Actual Revenue Performance$1,154 million (102.6% of goal)
    Final Payout Rate113.5% of the target amount
    Evaluation Period2023, with payout disbursed in February 2024
    WeightNot explicitly stated; revenue is the sole metric (implied 100%)

    Option Awards

    Grant DateOptions GrantedGrant Date Fair ValueGrant Date Stock PriceVesting Schedule
    January 26, 2023100,000 $2,687,936 $75.18 per share Vesting over 4 years: 1/4 vesting on January 1, 2024; remaining options vest ratably monthly over 36 months
    October 10, 202310,000 $208,458 $53.02 per share Vesting over 4 years: 1/4 vesting on September 1, 2024; remaining options vest ratably monthly over 36 months